New Four-Drug attack on Fast-Spreading lung cancer
NCT ID NCT05588388
Summary
This study is testing if adding a drug called bevacizumab to a standard three-drug treatment can better control an aggressive type of lung cancer that has spread to the liver. It will involve 39 adults with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination can keep the cancer from growing for a longer time and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER METASTASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
RECRUITINGLos Angeles, California, 90048, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact
Contact Email: •••••@•••••
Contact
-
V.A. Ann Arbor Healthcare System
RECRUITINGAnn Arbor, Michigan, 48105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.